Enliven Therapeutics appoints director Lori Kunkel to Nominating Committee

Enliven Therapeutics, Inc.

Dr. Lori Kunkel appointed to Nominating and Corporate Governance Committee effective May 29, 2024.
Her board appointment was reported April 9, 2024; committee role now determined.
Appointment follows recommendation of the Committee.

item 5.02

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-149141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.